Acetylsalicylic Acid vs. Metoprolol in Migraine Prophylaxis - A Double-Blind Cross-Over Study

1990 ◽  
Vol 30 (10) ◽  
pp. 639-641 ◽  
Author(s):  
K-H Grotemeyer ◽  
H-W Scharafinski ◽  
H-P Schlake ◽  
IW Husstedt
Cephalalgia ◽  
1988 ◽  
Vol 8 (3) ◽  
pp. 187-192 ◽  
Author(s):  
Marie Germaine Bousser ◽  
Jacques Chick ◽  
Eliane Fuseau ◽  
Thierry Soisson ◽  
Robert Thevenet

The efficacy of the combination of dihydroergotamine (10 mg) with acetylsalicylic acid (80 mg) (DHE + ASA) in the prophylaxis of migraine was studied in a double-blind, placebo-controlled crossover trial (8 weeks twice). Of 45 patients who entered the study, 38 completed it. The number of attacks was significantly ( p = 0.003) reduced during active treatment (11.5 ± 6.2) compared with placebo (16.6 ± 9.9). The mean duration, the mean severity, and the mean score for symptomatic acute medication of attacks did not differ significantly. The overall assessment made by the patients themselves was in favor of DHE + ASA ( p = 0.001). These results indicate a moderately beneficial effect of the dihydroergotamine/low-dose acetylsalicylic acid combination in migraine prophylaxis.


1988 ◽  
Vol 102 (1) ◽  
pp. 39-42 ◽  
Author(s):  
S. Kristensen ◽  
K. Tveteraas ◽  
P. Hein ◽  
H. B. Poulsen ◽  
K. E. Outzen

AbstractThe pain-relieving efficacy of naproxen and acetylsalicylic acid (ASA) in tonsillectomized patients was compared in a double blind parallel clinical trial comprising 83 patients, among whom 42 were treated with naproxen and 41 with ASA. The patients were treated post-operatively for two days with either naproxen suppositories 500 mg. twice, or ASA effervescent tablets 1000 mg. three times, daily.The therapeutic gain was evaluated by recording the intensity of pain, reduced ability to open the mouth (trismus), consumption of supplementary analgesic (parcetamol), and pain-related sleep disturbances.The statistical analysis of the results revealed no differences in pain intensity, consumption of additional analgesics or pain-related sleep disturbances in the two treatment groups. A considerable degree of trismus was demonstrated in most of the tonsillectomized patients. This reduced ability to open the mouth was gradually overcome in the naproxen group while it remained unchanged in the ASA group, however, no statistical significant difference could be demonstrated. Additionally, no significant positive correlation between pain intensity and trismus was proven. The pain-relieving effect, however, was unsatisfactory in both the naproxen and the ASA group, and clinical controlled trial studies of alternative analgetics in tonsillectomized patients are still to be encouraged.


2009 ◽  
Vol 16 (1) ◽  
pp. 88-94 ◽  
Author(s):  
R. O. Millán-Guerrero ◽  
S. Isais-Millán ◽  
S. Barreto-Vizcaíno ◽  
L. Rivera-Castaño ◽  
C. Rios-Madariaga

Cephalalgia ◽  
1987 ◽  
Vol 7 (6_suppl) ◽  
pp. 473-474
Author(s):  
G.D. Solomon ◽  
F.G. Freitag ◽  
N. Mehta ◽  
S. Diamond

Cephalalgia ◽  
1997 ◽  
Vol 17 (2) ◽  
pp. 109-112 ◽  
Author(s):  
TJ Steiner ◽  
LJ Findley ◽  
AWC Yuen

Lamotrigine blocks voltage-sensitive sodium channels, leading to inhibition of neuronal release of glutamate. Release of glutamate may be essential in the propagation of spreading cortical depression, which some believe is central to the genesis of migraine attacks. This study compared safety and efficacy of lamotrigine and placebo in migraine prophylaxis in a double-blind randomized parallel-groups trial. A total of 110 patients entered; after a 1-month placebo run-in period, placebo-responders and non-compliers were excluded, leaving 77 to be treated with lamotrigine ( n=37) or placebo ( n=40) for up to 3 months. Initially lamotrigine therapy was commenced at the full dose of 200 mg/day, but, following a high incidence of skin rashes, a slow dose-escalation was introduced: 25 mg/day for 2 weeks, 50 mg/day for 2 weeks, then 200 mg/day. Attack rates were reduced from baseline means of 3.6 per month on lamotrigine and 4.4 on placebo to 3.2 and 3.0 respectively during the last month of treatment. Improvements were greater on placebo and these changes, not statistically significant, indicate that lamotrigine is ineffective for migraine prophylaxis. There were more adverse events on lamotrigine than on placebo, most commonly rash. With slow dose-escalation their frequency was reduced and the rate of withdrawal for adverse events was similar in both treatment groups.


Cephalalgia ◽  
1991 ◽  
Vol 11 (11_suppl) ◽  
pp. 166-167
Author(s):  
K.N. Viswanathan ◽  
C. Rajendiran ◽  
D.S. Manohar ◽  
V. T. Balaraman

Sign in / Sign up

Export Citation Format

Share Document